Vitamin E and acute graft-versus-host disease after myeloablative allogeneic hematopoietic cell transplantation

Eur J Haematol. 2021 Mar;106(3):417-424. doi: 10.1111/ejh.13567. Epub 2020 Dec 19.

Abstract

Objectives: Vitamin E has antioxidant and immunomodulatory effects that might influence the development of acute graft-versus-host disease (GvHD). We investigated the association between plasma vitamin E levels and acute GvHD.

Methods: We studied 115 adults who underwent myeloablative allogeneic hematopoietic cell transplantation between July 2015 and August 2018. Vitamin E was measured by high-performance liquid chromatography in stored plasma samples obtained pre-transplantation at day -23 (±15 days) and post-transplantation at day +28 (±3 days).

Results: Pre-transplantation vitamin E levels were inversely associated with grade II-IV acute GvHD (hazard ratio 0.68 per 10 µmol/L increase, 95% confidence interval [CI]: 0.47-0.98). The association remained after adjustment for known prognostic factors for acute GvHD. Patients with levels below the median had a cumulative incidence of grade II-IV acute GvHD of 46% (CI: 33-59%) versus 21% (CI: 10-32%) in patients with levels above the median. No clear association with non-relapse mortality, relapse, or chronic GvHD was found. Post-transplantation vitamin E levels (measured in 72 [63%] patients) were correlated with pre-transplantation levels (ρ = .31) but were not associated with subsequent grade II-IV acute GvHD.

Conclusions: High pre-transplantation vitamin E levels were associated with less acute GvHD.

Keywords: acute graft-versus-host disease; allogeneic hematopoietic cell transplantation; vitamin E.

MeSH terms

  • Acute Disease
  • Biomarkers
  • Disease Susceptibility
  • Female
  • Graft vs Host Disease / blood*
  • Graft vs Host Disease / diagnosis
  • Graft vs Host Disease / etiology*
  • Hematopoietic Stem Cell Transplantation* / adverse effects
  • Hematopoietic Stem Cell Transplantation* / methods
  • Humans
  • Male
  • Myeloablative Agonists / administration & dosage
  • Postoperative Period
  • Severity of Illness Index
  • Time Factors
  • Transplantation Conditioning* / adverse effects
  • Transplantation Conditioning* / methods
  • Transplantation, Homologous
  • Vitamin E / blood*

Substances

  • Biomarkers
  • Myeloablative Agonists
  • Vitamin E